Implementation of pharmacogenetics in a clozapine treatment resistant patient: a case report

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Meltzer H , Kostakoglu A . Treatment resistant schizophrenia. In: Comprehensive Care of Schizophrenia – A Textbook of Clinical Management. Lieberman JA Murray RM (Eds). Martin Dunitz, London, 181–203 (2001).
  Google Scholar
• 2. Cervera Enguix S , Seva Fernández A . Pharmacological treatment resistant schizophrenia. Actas. Esp. Psiquiatr. 34(1), 48–54 (2016).
  Google Scholar
• 3. Kane J , Honigfeld G , Singer J et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789–96 (1998).
  Google Scholar
• 4. Remington G , Lee J , Agid O et al. Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert. Opin. Drug Saf. 15(9), 1193–203 (2016).
  Medline CASGoogle Scholar
• 5. Elkis H , Meltzer HY . Refractory schizophrenia. Rev. Bras. Psiquiatr 29(2), S41–S47 (2007).
  MedlineGoogle Scholar
• 6. Hasan A , Falkai P , Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry. 13(5), 318–378 (2012).
  MedlineGoogle Scholar
• 7. Mouaffak F , Tranulis C , Gourevitch R et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol. 29(1), 28–33 (2006).
  Medline CASGoogle Scholar
• 8. Remington G , Saha A , Chong SA et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19(10), 843–872 (2005).
  Medline CASGoogle Scholar
• 9. Zink M , Englisch S , Meyer-Lindenberg A . Polypharmacy in schizophrenia. Curr. Opin. Psychiatry. 23(2), 103–111 (2010).
  MedlineGoogle Scholar
• 10. Ulrich S , Baumann B , Wolf R et al. Therapeutic drug monitoring of clozapine and relapse – a retrospective study of routine clinical data. Int. J. Clin. Pharmacol. Ther. 41(1), 3–13 (2003). •• The Therapeutic drug monitoring of clozapine as atypical antipsychotic drug is recommended during maintenance treatment.
  Medline CASGoogle Scholar
• 11. Johnson JA . Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 19(11), 660–666 (2003).
  Medline CASGoogle Scholar
• 12. De Berardis D , Rapini G , Olivieri L et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther. Adv. Drug Saf. 9(5), 237–256 (2018).
  MedlineGoogle Scholar
• 13. Hiemke C , Bergemann N , Clement HW et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2017. Pharmacopsychiatry 51(1-02), 9–62 (2018). • Interesting guidelines that provides recommendations when to combine therapeutic drug monitoring with pharmacogenetic tests in neuropsychiatric drugs.
  Medline CASGoogle Scholar
• 14. Balan S , Bharathan SP , Vellichiramal NN et al. Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance. PLoS ONE 9(2), e89253 (2014).
  MedlineGoogle Scholar
• 15. Chen RY , Sham P , Chen EY et al. No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. Psychiatry Res. 105(3), 175–85 (2001).
  Medline CASGoogle Scholar
• 16. Cornelis MC , El-Sohemy A , Campos H . Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J. Med. Genet. 41(10), 758–762 (2004).
  Medline CASGoogle Scholar
• 17. Olajossy-Hilkesberger L , Godlewska B , Schosser-Haupt A et al. Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology 64(4), 202–210 (2011).
  Medline CASGoogle Scholar
• 18. Wendland JR , Martin BJ , Kruse MR , Lesch KP , Murphy DL . Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5‐HTTLPR and rs25531. Mol. Psychiatry 11(3), 224–226 (2006).
  Medline CASGoogle Scholar
• 19. Semang K , Babu R , Hearne S , Olsen M . Single nucleotide polymorphism genotyping using Kompetitive Allele Specific PCR (KASP): overview of the technology and its application in crop improvement. Mol. Breed. 33(1), 1–14 (2013).
  Google Scholar
• 20. Løvlie R , Daly AK , Molven A , Idle JR , Steen VM . Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. Mol. Bree. 392(1), 30–\34 (1996).
  CASGoogle Scholar
• 21. Couchman L , Morgan PE , Spencer EP et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther. Drug Monit. 32(4), 438–447 (2010).
  Medline CASGoogle Scholar
• 22. Rostami-Hodjegan A , Amin AM , Spencer EP et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol. 24(1), 70–78 (2004).
  Medline CASGoogle Scholar
• 23. Kohlrausch FB . Pharmacogenetics in schizophrenia: a review of clozapine studies. Braz. J. Psychiatry 35(3), 305–317 (2013). •• This review of the literature describes the main pharmacogenetic studies of clozapine and the genes that potentially influence response to treatment with this medication in schizophrenics.
  MedlineGoogle Scholar
• 24. Seppälä NH , Leinonen EV , Lehtonen ML et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol. Toxicol. 85(5), 244–246 (1999). •• Clozapine and norclozapine concentrations were about 40% lower in the smoking than in the nonsmoking group, due to an inducing effect of smoking on the cytochrome P450 (CYP)1A2, which is involved in the metabolism of clozapine. The dosage of clozapine was adjusted individually according to therapeutic response.
  Medline CASGoogle Scholar
• 25. Balibey H , Basoglu C , Lundgren S et al. CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia . Klinik Psikofarmakol. Bulteni. 21(2) 93–99 (2011). • Results suggest that the CYP1A2*1F/*1F genotype may be a risk factor for lack of response to clozapine treatment in psychotic patients, especially in cigarette smokers.
  CASGoogle Scholar
• 26. US FDA. Drugs@FDA: FDA approved drug products (Revised: 02/2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/019758s084lbl.pdf • The FDA-approved drug label for clozapine states that in poor metabolizers, a lower dose of clozapine may be necessary. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted.
  Google Scholar
• 27. Bilic P , Jukic V , Vilibic M et al. Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene 543(1), 125–132 (2014).
  Medline CASGoogle Scholar
• 28. Terzić T , Kastelic M , Dolžan V et al. Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia. Neuropsychiatr. Dis. Treat. 11, 453–459 (2015).
  Medline CASGoogle Scholar
• 29. Kohlrausch FB , Salatino-Oliveira A , Gama CS , Lobato MI , Belmonte-de-Abreu P , Hutz MH . Influence of serotonin transporter genepolymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res. 44(16), 158–162 (2010). •• These authors found that nonresponders to clozapine showed a higher frequency of S allele in the SLC6A4 gene.
  Google Scholar
• 30. Serretti A , Fabbri C , Pellegrini S et al. No Effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 10(2), 180–189 (2013).
  MedlineGoogle Scholar
• 31. Grover S , Sahoo S . Treatment of clozapine nonresponders. Curr. Treat. Options Psychiatry 6(1), 32–63 (2019).
  Google Scholar